Annual Congress: Hematologic Malignancies

2023 NCCN Hem Congress

Registration Open for the NCCN 2023 Annual Congress: Hematologic Malignancies™

Hilton San Francisco Union Square • San Francisco, California | Virtual attendance also available
Friday, September 22, 2023 – Saturday, September 23, 2023

Register now for great rates!
Learn More
Join us in San Francisco!
Register Now
Designed for the entire oncology team!
View Agenda

Latest Blood Cancer Treatment Updates Presented at Annual NCCN Event During Blood Cancer Awareness Month

Important Alert About Fraudulent Sites

Information about this Congress may appear on fraudulent websites that appear to offer registration, exhibit space, and hotel rooms at discounted rates. These companies are in no way affiliated with NCCN or the Hilton San Francisco Union Square. Please do not book any registrations or reservations through these sites, and register only through NCCN. If you have any questions or concerns, contact

Hilton San Francisco Union Square

Continuing Education

Chaired by Andrew D. Zelenetz, MD, PhD, from Memorial Sloan Kettering Cancer Center, this program features presentations and interactive discussions highlighting the treatment options and supportive care for a variety of hematologic malignancies. This program is approved for AMA PRA Category 1 Credit™ and ABIM, ABPath, and ABMS MOC for physicians and is also certified for credit for nurses, pharmacists, and other oncology professionals.

Disease areas to be covered:

  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
  • Chronic Myeloid Leukemia (CML)
  • Classical Hodgkin Lymphoma (CHL)
  • Mantle Cell Lymphoma (MCL)
  • Multiple Myeloma (MM)
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)
  • Waldenström Macroglobulinemia (WM)

Additional topics:

  • Anticoagulation and Antithrombotic Therapy
  • Bispecific T-cell Engagers
  • BTK Inhibitors
  • Graft-Versus-Host Disease
  • Toxicities in CAR T-cell Therapy
  • Updates in WHO/ICC Classification System

For CE program supporter opportunities, contact Lisa Perfidio, Senior Manager, CE Supporter Outreach.

This activity is supported through educational grants from:

  • AstraZeneca
  • Bristol Myers Squibb
  • Genentech, a member of the Roche Group
  • GSK
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Novartis
  • Sanofi
  • Seagen
  • Taiho Oncology, Inc.

This educational activity is supported by a medical education grant from:

  • Karyopharm Therapeutics

This educational activity is supported by independent educational grants from:

  •  AbbVie
  • Daiichi Sankyo
  • Incyte Corporation
  • Merck & Co., Inc., Rahway, NJ, USA.

This activity is supported by an unrestricted educational grant provided by:

  • Prothena Biosciences Ltd, Dublin, Ireland, a member of the Prothena Corporation plc group

Supported by a grant from:

  • Pfizer Inc.

Supported by an educational grant from:

  • Servier Pharmaceuticals LLC.



Exhibition Hall

View Exhibitor Prospectus


For exhibitor opportunities, contact Jennifer Tredwell, Vice President, Marketing and Communications

Save the dates!

NCCN 2024 Annual Congress: Hematologic Malignancies™
Friday, September 20, 2024 – Saturday, September 21, 2024
New York Marriott Marquis • New York, NY